Patents by Inventor Joel Bergman
Joel Bergman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10456394Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.Type: GrantFiled: February 15, 2017Date of Patent: October 29, 2019Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Alan Kozikowski, Sida Shen, Joel Bergman, Irina Gaisina
-
Publication number: 20190255046Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.Type: ApplicationFiled: February 15, 2017Publication date: August 22, 2019Applicant: The Board of Trustees of the University of IllinosInventors: Alan KOZIKOWSKI, Sida SHEN, Joel BERGMAN, Irina GAISINA
-
Patent number: 10227295Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: GrantFiled: September 5, 2017Date of Patent: March 12, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of The University of IllinoisInventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
-
Patent number: 9956192Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: GrantFiled: August 8, 2016Date of Patent: May 1, 2018Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of The University of IllinoisInventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
-
Publication number: 20170369428Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: ApplicationFiled: September 5, 2017Publication date: December 28, 2017Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
-
Patent number: 9751832Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: GrantFiled: July 30, 2014Date of Patent: September 5, 2017Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of the University of IllinoisInventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
-
Publication number: 20170035710Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: ApplicationFiled: August 8, 2016Publication date: February 9, 2017Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
-
Patent number: 9409858Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: GrantFiled: March 7, 2013Date of Patent: August 9, 2016Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of the University of IllinoisInventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
-
Publication number: 20160185716Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: ApplicationFiled: July 30, 2014Publication date: June 30, 2016Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Lagra, Karrune V. Woan
-
Patent number: 9249087Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.Type: GrantFiled: January 31, 2012Date of Patent: February 2, 2016Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butler, Joel Bergman, Wayne W. Hancock
-
Publication number: 20150056213Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.Type: ApplicationFiled: March 7, 2013Publication date: February 26, 2015Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
-
Patent number: 8918521Abstract: Embodiments are disclosed herein that are related to preserving battery life of a mobile device. One disclosed embodiment provides, for example, in a mobile device server, a method for sending messages to a mobile endpoint utilized concurrently with a non-mobile endpoint. The method comprises receiving a first message sent from a different user and sending the first message to the mobile endpoint. The method further comprises receiving a second message sent by the user from the non-mobile endpoint and, in response, suspending a session with the mobile endpoint. In response to receiving a third message from the mobile endpoint, the method comprises resuming the session with the mobile device.Type: GrantFiled: June 3, 2009Date of Patent: December 23, 2014Assignee: Microsoft CorporationInventors: Joel Bergman, Jon Changzheng Xu, Gerardo Garcia, Ashwini Kumar Varma
-
Publication number: 20140128408Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.Type: ApplicationFiled: January 31, 2012Publication date: May 8, 2014Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butier, Joel Bergman, Wayne W. Hancock
-
Publication number: 20100312830Abstract: Embodiments are disclosed herein that are related to preserving battery life of a mobile device. One disclosed embodiment provides, for example, in a mobile device server, a method for sending messages to a mobile endpoint utilized concurrently with a non-mobile endpoint. The method comprises receiving a first message sent from a different user and sending the first message to the mobile endpoint. The method further comprises receiving a second message sent by the user from the non-mobile endpoint and, in response, suspending a session with the mobile endpoint. In response to receiving a third message from the mobile endpoint, the method comprises resuming the session with the mobile device.Type: ApplicationFiled: June 3, 2009Publication date: December 9, 2010Applicant: MICROSOFT CORPORATIONInventors: Joel Bergman, Jon Changzheng Xu, Gerardo Garcia, Ashwini Kumar Varma
-
Patent number: RE47009Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.Type: GrantFiled: June 14, 2016Date of Patent: August 28, 2018Assignees: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Alan Kozikowski, Jay Hans Kalin, Kyle Vincent Butler, Joel Bergman, Wayne W. Hancock